Current ADA guidelines indicate that clinicians should prescribe a medication with demonstrated cardiovascular benefit for patients with ASCVD who are on metformin and are unable to achieve the A1c target. Specifically, they recommend a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist because several of these drugs have gained approval to reduce the risk for death in adults with T2D and cardiovascular disease. Factors informing the selection process may include considering whether the patient prefers oral or injectable administration, whether weight loss is a goal, and adverse effects and contraindications.
Learn more about SGLT2 inhibitors in T2D.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Diabetes Drugs - Medscape - May 13, 2022.
Comments